Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863772 · ClinicalTrials.gov registry record · Phase 3
Tanezumab and Nerve Function In Arthritis Patients
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT00863772 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 220 participants.
The verdict
NCT00863772, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
Tanezumab reduces pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves.
Interventions
- OTHER Placebo
- BIOLOGICAL tanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2009-05-18 |
| Est. Completion | 2010-11-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00863772
The ClinicalTrials.gov registry entry for NCT00863772 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00863772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00863772 about?
NCT00863772 is a clinical study titled "Tanezumab and Nerve Function In Arthritis Patients". Tanezumab reduces pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves.
What is the current status of trial NCT00863772?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2009-05-18. Estimated completion is 2010-11-16.
What interventions are being tested in trial NCT00863772?
The interventions under investigation include: Placebo (OTHER), tanezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00863772?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.